FDA Approves IMMGOLIS™ (golimumab-sldi) and IMMGOLIS INTRI™ (golimumab-sldi), First Biosimilars to Simponi® (golimumab) and Simponi Aria® (golimumab); Accord BioPharma to Lead U.S. Commercialization

FDA approval of IMMGOLIS and IMMGOLIS INTRI breaks new ground in patient access, marking the first biosimilar option to golimumab biologic therapy in the U.S. IMMGOLIS is approved for the treatment of adults with moderately to severely active rheumatoid arthritis (RA), in combination with...